Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRB | P23467 | 4/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.32 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.32 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | GUCY1B2 | O75343 | 1/20 | 0.31 |
| ▸ | GUCY1A2 | P33402 | 1/20 | 0.31 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9986968 | 0.73 | CTSL (0.32) | PTPRBCNR2SMN1; SMN2 | |
| SCHEMBL9980512 | 0.70 | CYP2C19 (0.35) | CNR2KMT2AMEN1OPRM1OPRD1 | |
| SCHEMBL3430267 | 0.69 | PTPRB (0.35) | PTPRBCNR2HDAC4HDAC6HDAC3 | |
| SCHEMBL20320353 | 0.69 | MAPT (0.32) | PTPRBMAPTCYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL3430970 | 0.68 | PTPRB (0.35) | PTPRBCNR2HDAC4HDAC6HDAC3 | |
| SCHEMBL18214807 | 0.68 | PTPRB (0.36) | PTPRBCNR2MAPTCYP2C9CYP2C19 | |
| SCHEMBL9980378 | 0.67 | MEN1 (0.33) | KMT2AMEN1OPRM1OPRD1 | |
| SCHEMBL9980407 | 0.67 | CYP2C19 (0.32) | KMT2AHDAC3MEN1CYP2C19KCNN4 | |
| SCHEMBL13095297 | 0.65 | PTPRB (0.33) | PTPRBMAPTCYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL13528448 | 0.65 | LMNA (0.37) | PTPRBHDAC4HDAC6HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3079701-B1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME (US) | 2021-08-11 | — | — | EP | disclosed |
| US-9611278-B2 | Soluble guanylate cyclase activators | MERCK SHARP & DOHME CORP. (US) | 2017-04-04 | — | — | US | disclosed |
| US-20160304536-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2016-10-20 | — | — | US | disclosed |
| EP-3079701-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | Merck Sharp & Dohme Corp. (US) | 2016-10-19 | — | — | EP | disclosed |
| US-9365574-B2 | Soluble guanylate cyclase activators | MERCK SHARP & DOHME CORP. (US) | 2016-06-14 | — | — | US | disclosed |
| EP-2575473-B1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2015088885-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2015-06-18 | — | — | WO | disclosed |
| EP-2575473-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | Merck Sharp & Dohme Corp. (US) | 2013-04-10 | — | — | EP | disclosed |
| US-20130072492-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME LLC | 2013-03-21 | — | — | US | disclosed |
| WO-2011149921-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072492-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | GUCY1A2, GUCY1A1, PDE2A | PTPRB 2400/4885CNR2 1438/4885HDAC4 4203/4885 |
| US-20160304536-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | GUCY1A1, GUCY1A2, PRKG1 | PTPRB 2202/4885CNR2 1537/4885HDAC4 4226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.